File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Is sentinel lymph node biopsy after neoadjuvant chemotherapy feasible in Chinese patients with invasive breast cancers?

TitleIs sentinel lymph node biopsy after neoadjuvant chemotherapy feasible in Chinese patients with invasive breast cancers?
Authors
KeywordsAxillary dissection
Breast cancer
Chinese
False-negative rate
Lymphatic mapping
Neoadjuvant chemotherapy
Sentinel lymph node biopsy
Issue Date2009
PublisherWiley-Blackwell Publishing Asia. The Journal's web site is located at http://www.blackwellpublishing.com/journals/ANS
Citation
Anz Journal Of Surgery, 2009, v. 79 n. 10, p. 719-723 How to Cite?
AbstractBackground: A wide variation in the accuracy of performance of sentinel lymph node biopsy (SLNB) following neoadjuvant chemotherapy in breast cancer has been reported despite its increased use. This study aimed to be the first to evaluate the feasibility and accuracy of SLNB after neoadjuvant chemotherapy in Chinese patients with breast cancer. Methods: A review of prospectively collected data from breast cancer patients who had SLNB after prior neoadjuvant chemotherapy was performed. A combination of radiopharmaceutical 99mTc-albumin colloid (Pharmalucence, MA, USA) and Patent Blue V dye (Guerbet, France) was used to identify the SLN. SLNB was followed by standard axillary dissection in all patients. Results: A total of 365 patients received SLNB from May 1999 to April 2006. A total of 78 patients with neoadjuvant chemotherapy followed by SLNB were recruited. The SLN identification rate, false-negative rate and accuracy rate were 83.3, 10.3 and 73.1%, respectively. Analysis was stratified into clinical and pathological response group. Location of the tumour was also found to be an important factor in affecting the false-negative rate (P = 0.019). For upper, outer quadrant tumour, five (32.3%, out of 16) patients presented with false-negative. Patients with more sentinel lymph node harvest had higher accuracy. A total of 22 patients had three or more lymph nodes harvested, and the false-negative rate was 21.7% (5 out of 23 patients) (P = 0.00). Conclusions: The results of our study show that SLNB is feasible and applicable in Chinese patients with breast cancer with operable disease who have received neoadjuvant chemotherapy. © 2009 Royal Australasian College of Surgeons.
Persistent Identifierhttp://hdl.handle.net/10722/130947
ISSN
2015 Impact Factor: 1.158
2015 SCImago Journal Rankings: 0.432
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorCheung, TTen_HK
dc.contributor.authorSuen, DTKen_HK
dc.contributor.authorKwong, Aen_HK
dc.date.accessioned2011-01-06T07:17:03Z-
dc.date.available2011-01-06T07:17:03Z-
dc.date.issued2009en_HK
dc.identifier.citationAnz Journal Of Surgery, 2009, v. 79 n. 10, p. 719-723en_HK
dc.identifier.issn1445-1433en_HK
dc.identifier.urihttp://hdl.handle.net/10722/130947-
dc.description.abstractBackground: A wide variation in the accuracy of performance of sentinel lymph node biopsy (SLNB) following neoadjuvant chemotherapy in breast cancer has been reported despite its increased use. This study aimed to be the first to evaluate the feasibility and accuracy of SLNB after neoadjuvant chemotherapy in Chinese patients with breast cancer. Methods: A review of prospectively collected data from breast cancer patients who had SLNB after prior neoadjuvant chemotherapy was performed. A combination of radiopharmaceutical 99mTc-albumin colloid (Pharmalucence, MA, USA) and Patent Blue V dye (Guerbet, France) was used to identify the SLN. SLNB was followed by standard axillary dissection in all patients. Results: A total of 365 patients received SLNB from May 1999 to April 2006. A total of 78 patients with neoadjuvant chemotherapy followed by SLNB were recruited. The SLN identification rate, false-negative rate and accuracy rate were 83.3, 10.3 and 73.1%, respectively. Analysis was stratified into clinical and pathological response group. Location of the tumour was also found to be an important factor in affecting the false-negative rate (P = 0.019). For upper, outer quadrant tumour, five (32.3%, out of 16) patients presented with false-negative. Patients with more sentinel lymph node harvest had higher accuracy. A total of 22 patients had three or more lymph nodes harvested, and the false-negative rate was 21.7% (5 out of 23 patients) (P = 0.00). Conclusions: The results of our study show that SLNB is feasible and applicable in Chinese patients with breast cancer with operable disease who have received neoadjuvant chemotherapy. © 2009 Royal Australasian College of Surgeons.en_HK
dc.languageeng-
dc.publisherWiley-Blackwell Publishing Asia. The Journal's web site is located at http://www.blackwellpublishing.com/journals/ANSen_HK
dc.relation.ispartofANZ Journal of Surgeryen_HK
dc.rightsThe definitive version is available at www3.interscience.wiley.com-
dc.subjectAxillary dissectionen_HK
dc.subjectBreast canceren_HK
dc.subjectChineseen_HK
dc.subjectFalse-negative rateen_HK
dc.subjectLymphatic mappingen_HK
dc.subjectNeoadjuvant chemotherapyen_HK
dc.subjectSentinel lymph node biopsyen_HK
dc.subject.meshAntineoplastic Agents - therapeutic use-
dc.subject.meshBreast Neoplasms - epidemiology - pathology - therapy-
dc.subject.meshHong Kong - epidemiology-
dc.subject.meshMastectomy - methods-
dc.subject.meshSentinel Lymph Node Biopsy - methods-
dc.titleIs sentinel lymph node biopsy after neoadjuvant chemotherapy feasible in Chinese patients with invasive breast cancers?en_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=1445-1433&volume=79&issue=10&spage=719&epage=723&date=2009&atitle=Is+sentinel+lymph+node+biopsy+after+neoadjuvant+chemotherapy+feasible+in+Chinese+patients+with+invasive+breast+cancers?-
dc.identifier.emailKwong, A: avakwong@hkucc.hku.hken_HK
dc.identifier.authorityKwong, A=rp01734en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1111/j.1445-2197.2009.05057.xen_HK
dc.identifier.pmid19878167en_HK
dc.identifier.scopuseid_2-s2.0-70350498908en_HK
dc.identifier.hkuros168603-
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-70350498908&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume79en_HK
dc.identifier.issue10en_HK
dc.identifier.spage719en_HK
dc.identifier.epage723en_HK
dc.identifier.isiWOS:000271263200014-
dc.publisher.placeAustraliaen_HK
dc.identifier.scopusauthoridCheung, TT=35338712800en_HK
dc.identifier.scopusauthoridSuen, DTK=8876971300en_HK
dc.identifier.scopusauthoridKwong, A=8913654300en_HK
dc.identifier.citeulike6059486-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats